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Infl  ammatory bowel disease (IBD) is associated 
with a hypercoagulable state and an increased risk 
for thromboembolism (1–3). The IBD-associated 
hypercoagulable state is manifested in systemic 
blood and in both intestinal and extraintestinal 
vascular beds. Although no single consistent co-
agulation abnormality has been identifi  ed, blood 
samples from patients with active IBD have re-
vealed thrombocytosis, accelerated thrombin 
generation, and increased circulating levels of 
thrombin–antithrombin (TAT) complexes (2–4). 
Clinical studies indicate that there is a substan-
tially increased incidence of extraintestinal throm-
boembolism in IBD patients (1, 2, 4), with the 
thromboembolism frequently manifested as deep 
vein thrombosis or a pulmonary embolism. Al-
though thrombosis is known to contribute to 
morbidity and mortality in IBD, the mechanisms 
that underlie the hypercoagulable state during in-
testinal infl  ammation remain poorly defi  ned.
Eff  orts to better understand the processes of 
hemostasis and coagulation in diff  erent pathologic 
conditions have revealed an intimate link be-
tween coagulation and the infl  ammatory response 
(5, 6). Infl  ammation appears to shift the hemo-
static mechanisms in favor of thrombosis by alter-
ing the three dominant anticoagulant pathways, 
i.e., the heparin–antithrombin system, the tis-
sue factor (TF) pathway inhibitor system, and 
the protein C anticoagulant pathway (5, 6). Al-
though clinical evidence suggests that these 
pathways are altered in IBD (7, 8), there is no 
direct evidence supporting the participation of 
the natural anticoagulant pathways in the induc-
tion of a prothrombotic state in either human 
or experimental IBD.
There is also emerging evidence that the 
coagulation pathways exert an infl  uence on the 
infl  ammatory response. Diff  erent components of 
the coagulation pathways, including thrombin 
and TF, appear to promote infl  ammation, whereas 
activated protein C exerts an antiinfl  ammatory 
eff  ect. For example, TF itself activates protease-
activated receptor (PAR) 2 and, to a lesser extent, 
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There is growing evidence for an interplay between infl  ammatory and coagulation pathways 
in acute and chronic infl  ammatory diseases. However, it remains unclear whether compo-
nents of the coagulation pathway, such as tissue factor (TF), contribute to intestinal infl  am-
mation, and whether targeting TF will blunt the infl  ammatory cell recruitment, tissue injury, 
and enhanced thrombus formation that occur in experimental colitis. Mice were fed 3% 
dextran sodium sulfate (DSS) to induce colonic infl  ammation, with some mice receiving a 
mouse TF-blocking antibody (muTF-Ab). The adhesion of leukocytes and platelets in colonic 
venules, light/dye-induced thrombus formation in cremaster muscle microvessels, as well as 
disease activity index, thrombin–antithrombin (TAT) complexes in plasma, and histopatho-
logic changes in the colonic mucosa were monitored in untreated and muTF-Ab–treated 
colitic mice. In untreated mice, DSS elicited the recruitment of adherent leukocytes and 
platelets in colonic venules, caused gross and histologic injury, increased plasma TAT com-
plexes, and enhanced thrombus formation in muscle arterioles. muTF-Ab prevented elevation 
in TAT complexes, reduced blood cell recruitment and tissue injury, and blunted thrombus 
formation in DSS colitic mice. These fi  ndings implicate TF in intestinal infl  ammation and 
support an interaction between infl  ammation and coagulation in experimental colitis.
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PAR1 (9), whereas thrombin is known to activate PAR1, 3, 
and 4 (10–12). The activation of PARs elicits the production 
of proinfl  ammatory cytokines (e.g., TNF-α and IL-6) and 
promotes leukocyte rolling in venules (13–15). The potential 
importance of a link between TF and PAR signaling is sup-
ported by the observation that anti-PAR strategies success-
fully blunt the infl  ammatory responses in diff  erent models of 
experimental colitis (16). Furthermore, mice that lack the cyto-
plasmic domain of TF exhibit an attenuated recruitment of 
rolling, adherent, and transmigrating leukocytes in postcapil-
lary venules after LPS challenge (17). Similarly, a small mole-
cule inhibitor of the TF-VIIa complex (BCX-3607) has been 
shown to attenuate the LPS-induced production of IL-6 and 
IL-8 in vitro (by human umbilical vein endothelial cells) and 
IL-6 in vivo (18). Despite the mounting evidence that impli-
cates TF and other components of the coagulation pathway as 
potential mediators of acute and chronic infl  ammatory re-
sponses, the involvement of these coagulation pathways in 
the initiation and/or propagation of intestinal infl  ammation 
has not been systematically assessed in experimental models of 
IBD, nor has the feasibility of targeting the infl  ammation–
coagulation interface to blunt infl  ammation and tissue injury 
been evaluated in such models.
The overall objective of this study was to determine whether 
TF contributes to the pathogenesis of intestinal infl  ammation. 
In addition, we determined whether the systemic procoagulant 
state and enhanced extraintestinal thrombus formation that are 
manifested in human IBD can be recapitulated in an animal 
model of experimental colitis. The role of TF in mediating these 
coagulation/thrombotic events was also evaluated.
RESULTS
Clinical indices of disease activity
All animals survived the dextran sodium sulfate (DSS) proto-
col, and experiments were performed on day 6. Mice fed 
DSS had symptoms of colitis (diarrhea, weight loss, or peri-
anal bleeding) 1–2 d after starting the DSS that progressed 
Figure 1.  Inhibition of TF abrogates the clinical indices of colitis. 
(A) Changes in DAI on days 0–6 of DSS treatment. Some mice received 
muTF-Ab on days 0 and 3. (B) Changes in body weight from days 0 to 6 
of DSS treatment. Values are reported as means ± SE. *, P < 0.05 versus 
water; #, P < 0.05 versus DSS.
Figure 2.  TF contributes to the histological damage and infl  am-
mation observed in the colon during colitis. Representative images of 
histology (A–C) and blinded histological scoring of colonic mucosa (D) at 
day 6 in mice receiving (A) water, (B) DSS, or (C) DSS + muTF-Ab. Values 
are reported as means ± SE. *, P < 0.05 versus water; #, P < 0.05 versus 
DSS. Bar, 100 μm.JEM VOL. 204, July 9, 2007  1597
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throughout the 6-d period. The time course of change in 
disease activity index (DAI) is shown in Fig. 1 A. Control 
mice receiving water showed no clinical signs (diarrhea, fecal 
occult blood, perianal bleeding, or weight loss) of spontane-
ous intestinal infl  ammation. Mouse TF-blocking antibody 
(muTF-Ab) treatment of mice receiving DSS resulted in a 
signifi  cantly lower DAI score on day 6 (Fig. 1 A), and the 
loss in body weight was minimal in the muTF-Ab–treated 
group (Fig. 1 B). Bleeding in the muTF-Ab–treated mice 
was not signifi  cantly altered when compared with untreated 
DSS controls.
Histopathology
Blinded histological injury scoring was quantifi  ed in the distal 
colon after 6 d of DSS treatment. Control animals showed no 
signs of infl  ammation (Fig. 2, A and D). In contrast, mice receiv-
ing DSS exhibited histologic signs of severe colitis, as assessed 
by overall score as well as specifi  c parameters (infl  ammation, 
extent, and crypt damage) (Fig. 2, B and D). Infl  ammation was 
mainly confi  ned to the mucosa and the submucosa, with a 
dense cellular infi  ltrate and partial loss of epithelial integrity. All 
of the histologic variables were signifi  cantly blunted by the 
muTF-Ab treatment regimen (Fig. 2, C and D).
Colonic microvascular responses
DSS treatment elicited an approximately sevenfold increase 
in the number of fi  rmly adherent leukocytes in colonic ven-
ules when compared with controls (Fig. 3 A). This increased 
recruitment of adherent leukocytes was virtually abolished 
by muTF-Ab treatment. Increased platelet adhesion was also 
noted in colonic venules of DSS-treated mice (Fig. 3 B), 
with the majority of the CFSE-stained, exogenous platelets 
binding to adherent leukocytes and the remainder adhering 
directly to colonic endothelial cells. Both platelet–leukocyte 
and platelet–endothelial cell adhesion were greatly attenu-
ated in DSS colitic mice treated with muTF-Ab.
Light/dye-induced thrombus formation
To characterize the contribution of TF to the extraintestinal 
coagulopathy associated with experimental colitis, we exam-
ined the eff  ects of DSS-induced colonic infl  ammation  on 
light/dye-induced thrombosis in cremaster muscle microves-
sels and compared the responses with those elicited by bacte-
rial endotoxin. Fig. 4 examines the thrombotic responses, 
expressed as the time of onset of platelet deposition/aggrega-
tion (left) and the time required for complete fl  ow cessation 
(right), in the light/dye-exposed microvessels of control, 
LPS-treated, and DSS colitic mice. The data confi  rm that 
much longer times are required for both the onset of throm-
bus formation and complete fl  ow cessation in arterioles, com-
pared with venules, of the control cremaster microcirculation 
exposed to light/dye, as previously reported (19). Although 
LPS treatment does appear to slightly aff  ect both variables 
in arterioles, the reductions in both the time of onset and 
time for fl  ow cessation in venules was more dramatic and 
signifi  cantly diff  erent. DSS colitis is also associated with a sig-
nifi  cantly altered thrombotic response that is consistent with a 
procoagulant state; however, this eff  ect was largely manifested 
in arterioles and not in venules.
Fig. 5 summarizes the changes in light/dye-induced throm-
bus formation in cremaster arterioles between untreated and 
muTF-Ab–treated mice on day 6 of DSS. The data show that 
the enhanced light/dye-induced thrombus formation in cre-
master arterioles of DSS mice is signifi  cantly blunted by TF 
immunoneutralization. The fi  gure also illustrates that treat-
ment of colitic mice on day 6 of DSS ( 30 min before light/
dye exposure) with the muTF-Ab (DSS + post–muTF-Ab) 
was as eff  ective as the pretreatment regimen (DSS + pre–
muTF-Ab), indicating that the presence of this reagent at 
the time of thrombus formation is suffi   cient to exert its bene-
fi  cial eff  ect.
Fig. 6 shows the eff  ect of muTF-Ab treatment on the 
changes in coagulation elicited by LPS in venules. It illustrates 
the complete normalization of light/dye-induced thrombus 
formation, which was signifi  cantly enhanced after LPS. Note 
Figure 3.  Ab blockade of TF virtually abolishes leukocyte and 
platelet recruitment in postcapillary venules of the colitic colon. 
Effects of treatment with muTF-Ab on the number of adherent leukocytes (A) 
and platelets (B) in the colonic microcirculation during DSS colitis. The 
shaded bar in B denotes the number of platelets bound directly to venular 
endothelium, whereas the open bar represents platelets binding to adher-
ent leukocytes. Values are reported as means ± SE. *, P < 0.05 versus 
water; #, P < 0.05 versus DSS.
Figure 4.  DSS and LPS enhance thrombus formation in arterioles 
and venules, respectively. (A) Time of onset of thrombus formation in 
cremaster arterioles and venules exposed to light/dye. (B) Time to cessation 
of fl  ow in the same vessels after light/dye exposure. Values are reported 
as means ± SE. *, P < 0.05 versus water.1598  TISSUE FACTOR MEDIATES INFLAMMATION IN COLITIS | Anthoni et al.
that this eff  ect is seen on the venular side in contrast to DSS, 
where this eff  ect is seen on the arteriolar side.
TAT measurements
The blood level of TAT complexes was signifi  cantly elevated 
in mice on DSS compared with control mice, which is con-
sistent with studies in IBD patients showing increased TAT 
levels and a systemic procoagulant state (4). Mice pretreated 
with the muTF-Ab showed no elevation in plasma TAT con-
centration on day 6 of DSS colitis (Fig. 7).
Control Ab does not alter injury in DSS colitis
To confi  rm that the protective eff  ect of muTF-Ab was not a 
byproduct of the administration of volume leading to a reduc-
tion in DSS intake and, therefore, colitis, a separate group of 
DSS mice was given an equivalent volume of an isotype-
matched control Ab. This treatment did not alter drinking vol-
ume, and the DSS load of these animals was above the threshold 
of 30 mg/g required for induction of colitis (20). The DAI 
score (3.3 ± 0.13; P < 0.0001 vs. water and muTF-Ab groups) 
and weight loss (93 ± 0.95% at day 6; P < 0.005 vs. water) re-
sponses in the control Ab–treated mice were similar to the values 
detected in untreated DSS mice. Thrombosis in extraintestinal 
vessels was also assessed in control Ab–treated mice. The time 
of onset of thrombosis (5.8 ± 0.43 s; P < 0.05 vs. water and 
both muTF-Ab groups) and cessation of fl  ow (14 ± 0.81 s) in 
arterioles did not diff  er from the responses noted in untreated 
DSS mice. These data confi  rm that the protective eff  ect of 
muTF-Ab was caused by blockade of TF rather than a non-
specifi  c eff  ect mediated by administration of Ab.
D  I  S  C  U  S  S  I  O  N 
Although studies of hemostasis and coagulation in diff  erent 
pathologic conditions have revealed an intimate link between 
coagulation and the infl  ammatory response, the relevance 
of this relationship to the pathophysiology of IBD remains 
poorly understood. There is a large amount of evidence that 
supports the notion that the coagulation cascade is activated 
in IBD and that this activation is manifested both in the in-
volved segment of the infl  amed bowel and at extraintestinal 
sites where potentially fatal thrombi are formed (2, 7, 8). 
Most of the evidence that implicates an activated coagulation 
cascade in IBD pathogenesis is derived from clinical studies, 
and there is relatively little information regarding the ability 
of animal models of IBD to recapitulate the hypercoagulable 
state that accompanies this disease. The results of this study 
provide novel insights into the link between gut infl  amma-
tion and coagulation, with evidence implicating the proco-
agulant TF in the infl  ammatory cell recruitment and tissue 
injury that accompany colonic infl  ammation. We also pro-
vide evidence that is consistent with a procoagulant state in 
the systemic blood of colitic mice, as refl  ected by elevated 
levels of TAT complexes in plasma and an enhanced ability 
of an extraintestinal vascular bed (cremaster muscle) to pro-
duce microthrombi in response to colonic infl  ammation. TF 
also appears to play a major role in the formation of these 
extraintestinal thrombi. Hence, our fi  ndings indicate that TF 
is a key molecule that acts at the infl  ammation–coagulation 
interface to promote both infl  ammation and coagulation in 
experimental IBD.
Our observation that immunoneutralization of TF very 
eff  ectively blunts the accumulation of adherent leukocytes 
and platelets in venules of the infl  amed colon is consistent 
with a previous report describing the ability of TF to in-
duce endothelial cells to assume a proadhesive phenotype (21). 
Whether this action of TF results from its ability to induce 
cytokine production via the PAR2 pathway or refl  ects a di-
rect eff  ect on the endothelial cell remains unclear. Although 
endothelial cells are an important source of TF in vivo (17, 
22–24), circulating monocytes and neutrophils are also known 
to produce and express the procoagulant (23–26). Hence, it 
is conceivable that leukocyte-associated TF could contribute 
to the TF-dependent blood cell recruitment responses elic-
ited in colonic venules by DSS. Studies on mouse chimeras 
wherein TF-defi  cient bone marrow is transplanted into WT 
recipients have revealed a major role for blood cell–associated 
TF in mediating the prothrombotic state and the generation 
of circulating infl  ammatory cytokines induced by LPS (27). 
This raises the possibility that exposure of blood cells to 
Figure 5.  DSS accelerates the onset of thrombus formation via 
a TF-dependent mechanism. Time of onset of thrombosis and cessation 
of fl  ow in arterioles of the cremaster after DSS and pretreatment (during 
the induction of colitis) or posttreatment (on the day of the experiment 
before thrombus induction) with muTF-Ab. Values are reported as 
means ± SE. *, P < 0.05 versus water; #, P < 0.05 versus DSS.
Figure 6.  TF participates in LPS-induced enhancement of throm-
botic responses. Time to onset of thrombosis and cessation of fl  ow in 
venules of the cremaster after LPS and treatment with muTF-Ab. Values 
are reported as means ± SE. *, P < 0.05 versus water.JEM VOL. 204, July 9, 2007  1599
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enteric bacteria-derived LPS (entering the interstitium through 
an injured mucosal membrane) during transit through the 
infl  amed bowel may contribute to the adhesion of leukocytes 
and platelets elicited by DSS. This is supported by the fi  nding 
that circulating cells such as neutrophils, eosinophils, and plate-
lets are capable of TF expression (25). Because the colonic tissue 
injury associated with DSS treatment is known to be neutrophil 
dependent, it appears likely that the attenuated histopathological 
changes observed in the muTF-Ab–treated mice refl  ect the di-
minished recruitment of injury-causing neutrophils. This possi-
bility is supported by a recent report describing an increased TF 
activity after renal ischemia-reperfusion that leads to neutro-
phil-mediated injury predominantly via thrombin-dependent 
PAR1 signaling (28).
Novel and potentially important observations in this study 
were the elevated TAT complex levels and enhanced light/
dye-induced thrombosis formation in extraintestinal micro-
vessels of mice with DSS-induced intestinal infl  ammation. 
These responses are consistent with clinical studies describing a 
hypercoagulable state in systemic blood and an increased inci-
dence of thromboembolism in IBD patients (1, 2). The 
magnitude of the increased TAT levels detected in the DSS 
model was quantitatively similar to the changes reported in 
human IBD (4). Although both arterial and venous circula-
tions appear to be involved in the thromboembolism that 
occurs in IBD patients, venous complications occur more 
frequently (1). In the present study, however, we noted that 
arterioles in the cremaster microcirculation, rather than ven-
ules, exhibit an enhanced thrombus formation in response to 
light/dye exposure. This is also in contrast to the pattern of 
microvessel susceptibility to thrombus formation observed 
after LPS administration wherein venules, but not arterioles, 
exhibit substantially enhanced thrombus formation, which has 
also been reported by others (19, 29, 30). The latter fi  ndings 
would argue against a role for LPS as a gut-derived mediator 
of the enhanced thrombus formation in cremaster arterioles 
during DSS-induced colonic infl  ammation.
Although the enhanced microthrombus formation ob-
served in cremaster muscle arterioles during DSS colitis is con-
sistent with the hypercoagulable state that has been repeatedly 
described in IBD patients, the pathophysiological relevance of 
these microvascular responses to the potentially fatal deep vein 
thrombosis and pulmonary vein thrombosis that occurs in 
some IBD patients remains unclear. It is conceivable that the 
thrombi that are found in large veins are initially formed in the 
microvasculature and seed the much larger thrombi that even-
tually develop in the large veins. This possibility is consistent 
with our observation that a large number of thrombi formed 
in both arterioles and venules dislodge from the vessel wall 
and eventually enter the blood stream (unpublished data).
Another major objective of this study was to determine 
whether TF contributes to the enhanced extraintestinal 
thrombus formation that accompanies DSS-induced colonic 
infl  ammation. Our data strongly support a role for TF in the 
enhanced thrombus formation and suggest that administration 
of the TF blocking Ab either as a pretreatment regimen dur-
ing the development of DSS colitis or as a posttreatment on 
the fi  nal day (30 min before thrombus induction/formation) 
is equally eff  ective in blunting the response. In addition to the 
therapeutic importance of these fi  ndings, it suggests that TF 
activation is not limited to the colonic microcirculation in this 
model. As noted above, this extraintestinal manifestation of a 
TF-dependent event may refl  ect the actions of infl  ammatory 
mediators released from the infl  amed colon that activate TF 
both locally and at the distant site, or it may refl  ect the pas-
sage of blood cells (e.g., monocytes and neutrophils) that are 
activated to produce TF as they fl  ow through the gut circulation 
and eventually transit through extraintestinal vascular beds, 
such as skeletal muscle. Additional work using bone marrow 
chimeras in TF-defi  cient mice is needed to resolve the contri-
bution of endothelial versus blood cell TF to the local and 
distant tissue responses during colonic infl  ammation.
In conclusion, our study provides the fi  rst evidence for a 
role for TF in mediating the infl  ammatory cell recruitment 
and tissue injury in the colon, as well as enhanced extraintes-
tinal thrombus formation during experimental colitis. These 
fi  ndings indicate that gut infl  ammation is accompanied by 
activation of a major coagulation pathway that, in turn, can 
propagate the infl  ammatory response in the bowel wall. Ex-
actly how these two responses interact with each other re-
mains unclear. As described earlier, TF can promote the 
acti  vation and/or release of many proinfl  ammatory and pro-
coagulant mediators, whereas infl  ammatory cytokines and other 
factors can stimulate TF production (31). This intimate link 
between coagulation and infl  ammation makes it diffi   cult to 
determine whether anti-TF is predominantly targeting one or 
both of these responses in our model. However, our fi  ndings 
are in agreement with other studies in which blocking co-
agulation pathways infl  uenced infl  ammatory responses dur-
ing IBD. For example, heparin has been shown to attenuate 
the infl  ammatory and injury responses in DSS colitis in mice 
(32) and trinitrobenzene sulphonic acid colitis in rats (33). 
Also, we have previously demonstrated a role for the CD40/
CD40L dyad, which is known to participate in both coagula-
tion and infl   ammatory processes, in the infl  ammatory  and 
thrombogenic responses to DSS colitis (34). Furthermore, the 
Figure 7.  Colitis increases circulating TAT complexes through 
a pathway that requires TF. TAT levels in plasma samples of DSS colitic 
mice with or without muTF-Ab treatment. Values are reported as 
means ± SE. *, P < 0.05 versus water; #, P < 0.05 versus DSS.1600  TISSUE FACTOR MEDIATES INFLAMMATION IN COLITIS | Anthoni et al.
triazolopyrimidine trapidil, which was developed for the pre-
vention of restenosis after vascular injury, was shown to protect 
against DSS-induced colonic infl  ammation, suggesting that tar-
geting coagulation may interfere with the development of the 
infl  ammatory response. Therapeutic strategies that target this 
vicious cycle of infl  ammation and coagulation may prove eff  ec-
tive in reducing the morbidity and mortality of chronic infl  am-
matory diseases such as IBD.
MATERIALS AND METHODS
Animals. Male C57BL/6J mice were purchased from the Jackson Labora-
tory and were maintained under pathogen-free conditions, with ad libitum 
access to a standard diet and water until reaching the desired age (8–10 wk) 
and/or weight (20–25 g). All animal procedures were reviewed and ap-
proved by the Institutional Animal Care and Use Committee of the Louisi-
ana State University Health Sciences Center and were performed according 
to the criteria outlined by the National Institutes of Health.
Induction of colitis. Mice received 3% DSS (40 kD; MP Biomedicals) in 
fi  lter-purifi  ed drinking water for 6 d ad libitum (35). Control mice received 
fi  ltered water alone.
Assessment of disease progression. DAI, ranging from 0 to 4, was used 
for clinical assessment of disease severity and calculated using stool consis-
tency, fecal blood, macroscopic evaluation of the anus, and weight loss, as 
previously described (36, 37).
Histological colitis score. For each animal, three samples of the distal co-
lon were evaluated histologically after staining with hematoxylin and eosin. 
Quantifi  cation of the histological changes was performed using a previously 
described scoring system (38).
Blood sampling and platelet preparation. Platelets monitored in the 
intravital microscopy experiments were harvested from donor mice (not 
receiving DSS) for labeling with the fl  uorochrome CFSE (90-μM fi  nal 
concentration; Invitrogen), as previously described (39). Leukocytes accounted 
for <0.01% of the cells in the fi  nal platelet suspension.
Surgical preparation for intravital microscopy. Mice were anesthe-
tized with 150 mg/kg ketamine hydrochloride i.p. and 7.5 mg/kg xylazine 
i.p. The right carotid artery was cannulated for blood pressure measure-
ments, and the right jugular vein was cannulated for infusion of rhodamine 
6G (Sigma-Aldrich) for leukocyte labeling, followed by infusion of CFSE-
labeled platelets. A laparotomy was performed, and the animal was placed on 
an adjustable acrylic microscope stage for visualization of venules in the 
proximal large bowel (40).
Intravital fl  uorescence microscopy. Platelets and leukocytes were visu-
alized with an inverted fl  uorescence microscope (DIAPHOT 300; Nikon) (40). 
The video images of fi  ve randomly selected postcapillary venules were cap-
tured with a CCD camera (C2400; Hamamatsu Photonics K.K.) and were 
digitally recorded, each for 1 min. Venular diameter (20–40 μm) was mea-
sured with a video caliper. Platelets and leukocytes were classifi  ed according 
to their interaction with the venular wall as either free fl  owing or adherent 
(cells remaining stationary for ≥30 s, expressed as the number of cells per 
square millimeter of venular surface).
TAT complex measurements. TAT complex concentrations in plasma 
were measured spectrophotometrically (492 nm) using a sandwich enzyme 
immunoassay (Enzygnost TAT micro; Dade Behring) (17, 41). The blood 
samples were obtained from separate groups of mice not subjected to other 
manipulation, and withdrawn from a venous canula into heparin to avoid 
artifi  cial activation.
Thrombus formation in cremaster muscle microcirculation. Mice 
were anesthetized with 50 mg/kg sodium pentobarbital i.p., and the cremaster 
muscle was surgically prepared for intravital fl  uorescence microscopic 
ob  servation, as previously described (42). Arterioles and venules (30–45-μm 
diameters) with shear rates of >400 s−1 were selected for study. Thrombosis 
formation in cremasteric microvessels was induced in mice receiving 10 ml/kg 
FITC-dextran i.v., which was allowed to circulate for 10–15 min before 
photoactivation (19, 29, 30). Blood cell velocities and shear rates were deter-
mined in arterioles and venules before photoactivation, which was initiated 
by exposing a 100-μm length of microvessel (venules fi  rst, followed by arte-
rioles) to epiillumination with a 175-W xenon lamp and a fl  uorescein fi  lter 
cube. Daily measurements of excitation power density were obtained to 
maintain a value within 1% of 1.4 W/cm2, as previously described (29). Epi-
illumination was continuously applied, and thrombus formation was quanti-
fi  ed by determining (a) the time of onset of platelet deposition/aggregation 
within the microvessel and (b) the time required for complete fl  ow cessation 
(>60 s) (19). Two to three thrombi were induced in each mouse, and the 
results of each vessel type (arterioles and venules) were averaged.
Experimental protocols. In the fi  rst series of experiments (n = 6), we 
focused on the macroscopic and histologic responses of the colon to DSS in 
WT mice treated with 20 mg/kg of body weight of the muTF-mAb 1H1 
(43), which was administered i.p. two times (200 μl/injection on days 0 and 3) 
during the course of colitis induction (DSS + TF-Ab group). A separate 
group of DSS mice was treated with 20 mg/kg of body weight of an isotype-
matched control Ab (rat IgG2A; eBioscience), using the same protocol. On 
day 6, leukocyte and platelet adhesion in the colonic microvasculature was 
quantifi  ed. After recording the adhesion responses, the mice were killed 
with an overdose of anesthetic, and the colon was excised for measurement 
of bowel length and weight and then divided for histologic processing.
Separate experiments were performed to evaluate thrombus formation 
in the cremaster microcirculation of DSS-treated mice. Some of these mice 
were pretreated in a manner similar to that described for the gut infl  amma-
tion experiments (DSS + pre–muTF-Ab), except that the cremaster muscle 
was evaluated on day 6 of DSS treatment for the onset of thrombus forma-
tion and cessation of fl  ow after light/dye exposure. Another group of colitic 
mice received the muTF-Ab (DSS + post–muTF-Ab) on day 6 of DSS, 
 30 min before light/dye exposure, to examine the effi   cacy of TF immu-
noneutralization after the onset of colitis. Because bacterial endotoxin has 
been extensively used to evaluate thrombus formation in the cremaster mus-
cle microcirculation, we also evaluated the thrombus formation in mice 
receiving 1.5 × 106 EU/kg of Escherichia coli endotoxin 0111:B4 (LPS; 
Sigma-Aldrich), as previously described (19). TAT measurements were ob-
tained in a separate series of mice (n = 10 per group) to avoid any interfer-
ence of the fl  uorescent dyes used in the intravital microscopy experiments 
with the color reaction in the TAT assay.
Data analysis. Statistical analyses were performed using one-way analysis of 
variance, followed by the Scheff  é post-hoc test. All values are reported as 
means ± SE. Statistical signifi  cance was set at P < 0.05.
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